Share Price and Basic Stock Data
Last Updated: October 28, 2025, 7:26 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Themis Medicare Ltd operates in the pharmaceuticals sector, with a market capitalization of ₹1,187 Cr and a share price of ₹129. The company’s revenue trajectory has shown fluctuations over the past quarters, with sales reported at ₹94 Cr in June 2022, declining to ₹80 Cr by March 2023, before rebounding to ₹105 Cr by September 2023. However, sales dipped again to ₹83 Cr in December 2023, illustrating volatility in revenue generation. Annual sales figures have also fluctuated, with revenues recorded at ₹395 Cr in March 2022, declining to ₹354 Cr in March 2023, before recovering to ₹382 Cr in March 2024. This trend highlights the company’s challenges in maintaining consistent revenue growth amidst operational pressures. The operating profit margin (OPM) has also been negative in recent quarters, indicating difficulties in managing costs effectively. Overall, while Themis Medicare has shown some resilience in revenue recovery, the inconsistency in sales performance raises concerns about future revenue stability.
Profitability and Efficiency Metrics
Themis Medicare’s profitability metrics indicate significant challenges. The company reported a net profit of ₹30 Cr for the year ending March 2025, down from ₹57 Cr in March 2023, and a net profit margin of just 5.89% for the same period. The operating profit margin (OPM) stood at -10% for the year, reflecting ongoing operational inefficiencies. The interest coverage ratio (ICR) of 5.35x suggests that the company is capable of meeting its interest obligations; however, the declining net profit and negative OPM signal underlying issues in cost management and revenue generation. Efficiency ratios such as return on equity (ROE) and return on capital employed (ROCE) are at 7.65% and 10.4% respectively, which are lower than typical industry standards, indicating that the company is not utilizing its equity and capital as effectively as it could. Furthermore, the cash conversion cycle (CCC) of 250 days points to inefficiencies in managing working capital, suggesting that Themis Medicare needs to improve its operational processes to enhance profitability.
Balance Sheet Strength and Financial Ratios
Themis Medicare’s balance sheet reflects a moderate financial position with total assets reported at ₹588 Cr and total liabilities at ₹588 Cr as of March 2025. The company’s reserves stood at ₹393 Cr, indicating a solid equity base relative to its total liabilities. Borrowings amounted to ₹83 Cr, which positions the company with a low debt-to-equity ratio of 0.20, suggesting that Themis Medicare is not overly leveraged. The current ratio of 1.95 indicates adequate short-term liquidity, while the quick ratio of 1.41 reflects a reasonable ability to cover immediate liabilities. However, the price-to-book value (P/BV) ratio of 3.35x indicates that the stock may be overvalued compared to its book value, which could deter potential investors. Overall, while the company exhibits a solid capital structure, the high P/BV ratio combined with declining profitability metrics raises questions about the sustainability of its financial health moving forward.
Shareholding Pattern and Investor Confidence
Themis Medicare’s shareholding pattern shows a strong promoter holding at 67.15%, reflecting significant insider confidence in the company’s prospects. However, foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold minimal stakes at 0.09% and 0.01%, respectively, suggesting a lack of institutional interest which could impact stock liquidity. The public holding stands at 32.75%, which indicates a diverse shareholder base but also highlights the potential volatility associated with retail investor sentiment. The number of shareholders has increased from 6,126 in September 2022 to 19,335 by June 2025, indicating growing retail interest. This increase in shareholder numbers could be a positive sign of investor confidence, despite the overall low institutional investment. The limited institutional participation may pose risks in terms of stock price stability during market fluctuations. Hence, while the promoter holding reflects confidence, the lack of institutional backing could raise concerns about long-term investor sentiment.
Outlook, Risks, and Final Insight
The future outlook for Themis Medicare appears to be mixed, characterized by both opportunities and risks. On the one hand, the company’s strong promoter holding and increasing number of shareholders suggest potential for future growth and stability. However, the volatility in revenue, negative operating margins, and declining profitability metrics highlight significant operational challenges that need to be addressed. Risks include ongoing inefficiencies in cost management, as evidenced by the negative OPM and high cash conversion cycle, which could hinder future profitability. Additionally, the low institutional interest raises concerns about market perception and stock liquidity. To navigate these challenges, Themis Medicare may need to implement strategic operational improvements and enhance investor relations. If the company can stabilize its revenue streams and improve profitability, it may attract more institutional interest and bolster investor confidence, paving the way for sustainable growth. Conversely, failure to address these operational inefficiencies could result in further declines in market perception and financial performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Themis Medicare Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 144 Cr. | 114 | 247/84.3 | 32.8 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.80 Cr. | 1.99 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,983 Cr. | 460 | 479/192 | 112 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.6 Cr. | 48.0 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 32.2 Cr. | 22.0 | 29.1/17.0 | 33.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,766.58 Cr | 1,179.77 | 50.40 | 194.36 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 94 | 91 | 89 | 80 | 97 | 105 | 83 | 98 | 123 | 117 | 94 | 72 | 98 |
| Expenses | 74 | 70 | 74 | 70 | 75 | 92 | 74 | 89 | 94 | 100 | 88 | 79 | 108 |
| Operating Profit | 20 | 21 | 15 | 10 | 22 | 12 | 8 | 9 | 29 | 17 | 6 | -8 | -10 |
| OPM % | 22% | 23% | 17% | 13% | 22% | 12% | 10% | 10% | 24% | 15% | 6% | -11% | -10% |
| Other Income | 6 | 6 | 7 | 5 | 6 | 7 | 6 | 5 | 7 | 6 | 1 | 2 | 1 |
| Interest | 2 | 2 | 2 | 3 | 2 | 2 | 3 | 2 | 2 | 2 | 3 | 2 | 2 |
| Depreciation | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 3 | 3 | 3 |
| Profit before tax | 22 | 23 | 18 | 10 | 23 | 14 | 8 | 9 | 31 | 18 | 2 | -11 | -14 |
| Tax % | 21% | 21% | 24% | 18% | 19% | 19% | 10% | 24% | 21% | 20% | 69% | -13% | 1% |
| Net Profit | 17 | 18 | 13 | 8 | 18 | 11 | 7 | 7 | 25 | 14 | 1 | -10 | -14 |
| EPS in Rs | 1.89 | 1.93 | 1.45 | 0.91 | 1.98 | 1.23 | 0.80 | 0.72 | 2.68 | 1.55 | 0.06 | -1.05 | -1.54 |
Last Updated: August 20, 2025, 2:15 am
Below is a detailed analysis of the quarterly data for Themis Medicare Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 98.00 Cr.. The value appears strong and on an upward trend. It has increased from 72.00 Cr. (Mar 2025) to 98.00 Cr., marking an increase of 26.00 Cr..
- For Expenses, as of Jun 2025, the value is 108.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 79.00 Cr. (Mar 2025) to 108.00 Cr., marking an increase of 29.00 Cr..
- For Operating Profit, as of Jun 2025, the value is -10.00 Cr.. The value appears to be declining and may need further review. It has decreased from -8.00 Cr. (Mar 2025) to -10.00 Cr., marking a decrease of 2.00 Cr..
- For OPM %, as of Jun 2025, the value is -10.00%. The value appears strong and on an upward trend. It has increased from -11.00% (Mar 2025) to -10.00%, marking an increase of 1.00%.
- For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
- For Depreciation, as of Jun 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -14.00 Cr.. The value appears to be declining and may need further review. It has decreased from -11.00 Cr. (Mar 2025) to -14.00 Cr., marking a decrease of 3.00 Cr..
- For Tax %, as of Jun 2025, the value is 1.00%. The value appears to be increasing, which may not be favorable. It has increased from -13.00% (Mar 2025) to 1.00%, marking an increase of 14.00%.
- For Net Profit, as of Jun 2025, the value is -14.00 Cr.. The value appears to be declining and may need further review. It has decreased from -10.00 Cr. (Mar 2025) to -14.00 Cr., marking a decrease of 4.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -1.54. The value appears to be declining and may need further review. It has decreased from -1.05 (Mar 2025) to -1.54, marking a decrease of 0.49.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 3:43 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 195 | 202 | 232 | 217 | 210 | 184 | 202 | 231 | 395 | 354 | 382 | 406 |
| Expenses | 171 | 184 | 194 | 184 | 184 | 181 | 166 | 181 | 299 | 287 | 330 | 356 |
| Operating Profit | 24 | 18 | 38 | 33 | 25 | 2 | 36 | 49 | 96 | 67 | 52 | 49 |
| OPM % | 12% | 9% | 16% | 15% | 12% | 1% | 18% | 21% | 24% | 19% | 13% | 12% |
| Other Income | 5 | 13 | 3 | 4 | 6 | 5 | 12 | 13 | 18 | 25 | 24 | 11 |
| Interest | 16 | 15 | 12 | 12 | 12 | 12 | 13 | 13 | 9 | 10 | 9 | 10 |
| Depreciation | 9 | 11 | 12 | 7 | 7 | 8 | 8 | 9 | 9 | 10 | 12 | 10 |
| Profit before tax | 4 | 5 | 17 | 18 | 11 | -13 | 27 | 41 | 95 | 73 | 53 | 40 |
| Tax % | 32% | -20% | 11% | 9% | 1% | -15% | 8% | 14% | 23% | 22% | 19% | 25% |
| Net Profit | 3 | 6 | 16 | 16 | 11 | -11 | 25 | 36 | 73 | 57 | 44 | 30 |
| EPS in Rs | 0.32 | 0.73 | 1.91 | 1.77 | 1.23 | -1.17 | 2.70 | 3.88 | 7.92 | 6.18 | 4.73 | 3.24 |
| Dividend Payout % | 28% | 25% | 9% | 0% | 0% | 0% | 6% | 11% | 6% | 8% | 11% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 100.00% | 166.67% | 0.00% | -31.25% | -200.00% | 327.27% | 44.00% | 102.78% | -21.92% | -22.81% | -31.82% |
| Change in YoY Net Profit Growth (%) | 0.00% | 66.67% | -166.67% | -31.25% | -168.75% | 527.27% | -283.27% | 58.78% | -124.70% | -0.89% | -9.01% |
Themis Medicare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 15% |
| 3 Years: | 1% |
| TTM: | -7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 4% |
| 3 Years: | -25% |
| TTM: | -118% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 24% |
| 3 Years: | 8% |
| 1 Year: | -59% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 15% |
| 3 Years: | 12% |
| Last Year: | 8% |
Last Updated: September 5, 2025, 1:46 pm
Balance Sheet
Last Updated: June 16, 2025, 11:12 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Reserves | 48 | 51 | 66 | 143 | 160 | 149 | 174 | 209 | 278 | 330 | 368 | 393 |
| Borrowings | 148 | 140 | 128 | 82 | 80 | 82 | 100 | 87 | 80 | 92 | 96 | 83 |
| Other Liabilities | 79 | 77 | 73 | 54 | 56 | 74 | 67 | 65 | 61 | 82 | 93 | 102 |
| Total Liabilities | 284 | 277 | 275 | 289 | 305 | 314 | 350 | 371 | 428 | 514 | 566 | 588 |
| Fixed Assets | 121 | 122 | 117 | 124 | 126 | 123 | 116 | 133 | 144 | 162 | 168 | 172 |
| CWIP | 12 | 4 | 6 | 9 | 2 | 2 | 8 | 2 | 3 | 3 | 3 | 3 |
| Investments | 4 | 5 | 6 | 23 | 24 | 27 | 35 | 45 | 56 | 70 | 89 | 95 |
| Other Assets | 147 | 146 | 146 | 133 | 153 | 162 | 191 | 191 | 225 | 279 | 307 | 318 |
| Total Assets | 284 | 277 | 275 | 289 | 305 | 314 | 350 | 371 | 428 | 514 | 566 | 588 |
Below is a detailed analysis of the balance sheet data for Themis Medicare Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 9.00 Cr..
- For Reserves, as of Mar 2025, the value is 393.00 Cr.. The value appears strong and on an upward trend. It has increased from 368.00 Cr. (Mar 2024) to 393.00 Cr., marking an increase of 25.00 Cr..
- For Borrowings, as of Mar 2025, the value is 83.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 96.00 Cr. (Mar 2024) to 83.00 Cr., marking a decrease of 13.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 102.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 93.00 Cr. (Mar 2024) to 102.00 Cr., marking an increase of 9.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 588.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 566.00 Cr. (Mar 2024) to 588.00 Cr., marking an increase of 22.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 172.00 Cr.. The value appears strong and on an upward trend. It has increased from 168.00 Cr. (Mar 2024) to 172.00 Cr., marking an increase of 4.00 Cr..
- For CWIP, as of Mar 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 3.00 Cr..
- For Investments, as of Mar 2025, the value is 95.00 Cr.. The value appears strong and on an upward trend. It has increased from 89.00 Cr. (Mar 2024) to 95.00 Cr., marking an increase of 6.00 Cr..
- For Other Assets, as of Mar 2025, the value is 318.00 Cr.. The value appears strong and on an upward trend. It has increased from 307.00 Cr. (Mar 2024) to 318.00 Cr., marking an increase of 11.00 Cr..
- For Total Assets, as of Mar 2025, the value is 588.00 Cr.. The value appears strong and on an upward trend. It has increased from 566.00 Cr. (Mar 2024) to 588.00 Cr., marking an increase of 22.00 Cr..
Notably, the Reserves (393.00 Cr.) exceed the Borrowings (83.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -124.00 | -122.00 | -90.00 | -49.00 | -55.00 | -80.00 | -64.00 | -38.00 | 16.00 | -25.00 | -44.00 | -34.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 74 | 82 | 75 | 81 | 120 | 145 | 186 | 123 | 93 | 149 | 170 | 159 |
| Inventory Days | 280 | 246 | 243 | 250 | 253 | 287 | 315 | 272 | 150 | 213 | 188 | 233 |
| Days Payable | 240 | 237 | 145 | 163 | 156 | 187 | 171 | 143 | 79 | 123 | 126 | 142 |
| Cash Conversion Cycle | 114 | 91 | 172 | 168 | 216 | 244 | 330 | 251 | 164 | 239 | 232 | 250 |
| Working Capital Days | -17 | -20 | -17 | -16 | 19 | -1 | 37 | 51 | 72 | 110 | 116 | 121 |
| ROCE % | 10% | 9% | 15% | 13% | 10% | -1% | 15% | 18% | 30% | 20% | 14% | 10% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 322 | 0.08 | 0.01 | 322 | 2025-04-22 17:25:18 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 3.24 | 4.73 | 61.83 | 79.22 | 38.86 |
| Diluted EPS (Rs.) | 3.24 | 4.72 | 61.73 | 79.07 | 38.84 |
| Cash EPS (Rs.) | 3.68 | 4.02 | 58.44 | 77.19 | 37.85 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 43.74 | 41.03 | 368.85 | 312.48 | 237.80 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 43.74 | 41.03 | 368.85 | 312.48 | 237.80 |
| Revenue From Operations / Share (Rs.) | 44.06 | 41.48 | 385.02 | 428.91 | 251.04 |
| PBDIT / Share (Rs.) | 5.84 | 6.11 | 85.80 | 111.06 | 57.81 |
| PBIT / Share (Rs.) | 4.76 | 4.78 | 74.39 | 100.75 | 48.50 |
| PBT / Share (Rs.) | 3.67 | 3.76 | 64.00 | 91.22 | 34.67 |
| Net Profit / Share (Rs.) | 2.60 | 2.69 | 47.03 | 66.89 | 28.54 |
| NP After MI And SOA / Share (Rs.) | 3.24 | 4.73 | 61.83 | 79.22 | 38.86 |
| PBDIT Margin (%) | 13.24 | 14.73 | 22.28 | 25.89 | 23.02 |
| PBIT Margin (%) | 10.79 | 11.52 | 19.32 | 23.49 | 19.32 |
| PBT Margin (%) | 8.32 | 9.07 | 16.62 | 21.26 | 13.81 |
| Net Profit Margin (%) | 5.89 | 6.47 | 12.21 | 15.59 | 11.37 |
| NP After MI And SOA Margin (%) | 7.35 | 11.40 | 16.05 | 18.46 | 15.47 |
| Return on Networth / Equity (%) | 7.41 | 11.52 | 16.76 | 25.35 | 16.33 |
| Return on Capital Employeed (%) | 10.13 | 10.68 | 18.26 | 29.12 | 18.35 |
| Return On Assets (%) | 5.07 | 7.68 | 11.07 | 17.03 | 9.61 |
| Long Term Debt / Equity (X) | 0.04 | 0.07 | 0.08 | 0.08 | 0.10 |
| Total Debt / Equity (X) | 0.20 | 0.25 | 0.27 | 0.27 | 0.36 |
| Asset Turnover Ratio (%) | 0.70 | 0.70 | 0.75 | 1.05 | 0.67 |
| Current Ratio (X) | 1.95 | 1.90 | 1.90 | 1.96 | 1.45 |
| Quick Ratio (X) | 1.41 | 1.44 | 1.41 | 1.40 | 0.98 |
| Inventory Turnover Ratio (X) | 5.24 | 1.21 | 1.48 | 1.90 | 1.20 |
| Dividend Payout Ratio (NP) (%) | 15.42 | 10.57 | 8.08 | 5.42 | 4.50 |
| Dividend Payout Ratio (CP) (%) | 11.57 | 8.25 | 6.82 | 4.80 | 3.63 |
| Earning Retention Ratio (%) | 84.58 | 89.43 | 91.92 | 94.58 | 95.50 |
| Cash Earning Retention Ratio (%) | 88.43 | 91.75 | 93.18 | 95.20 | 96.37 |
| Interest Coverage Ratio (X) | 5.35 | 6.00 | 8.26 | 11.64 | 4.18 |
| Interest Coverage Ratio (Post Tax) (X) | 3.38 | 3.64 | 5.53 | 8.01 | 3.06 |
| Enterprise Value (Cr.) | 1419.92 | 2092.17 | 1146.53 | 910.58 | 312.04 |
| EV / Net Operating Revenue (X) | 3.50 | 5.48 | 3.24 | 2.31 | 1.35 |
| EV / EBITDA (X) | 26.43 | 37.19 | 14.52 | 8.91 | 5.87 |
| MarketCap / Net Operating Revenue (X) | 3.33 | 5.28 | 3.03 | 2.18 | 1.12 |
| Retention Ratios (%) | 84.57 | 89.42 | 91.91 | 94.57 | 95.49 |
| Price / BV (X) | 3.35 | 5.34 | 3.16 | 2.99 | 1.18 |
| Price / Net Operating Revenue (X) | 3.33 | 5.28 | 3.03 | 2.18 | 1.12 |
| EarningsYield | 0.02 | 0.02 | 0.05 | 0.08 | 0.13 |
After reviewing the key financial ratios for Themis Medicare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 3.24. This value is below the healthy minimum of 5. It has decreased from 4.73 (Mar 24) to 3.24, marking a decrease of 1.49.
- For Diluted EPS (Rs.), as of Mar 25, the value is 3.24. This value is below the healthy minimum of 5. It has decreased from 4.72 (Mar 24) to 3.24, marking a decrease of 1.48.
- For Cash EPS (Rs.), as of Mar 25, the value is 3.68. This value is within the healthy range. It has decreased from 4.02 (Mar 24) to 3.68, marking a decrease of 0.34.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 43.74. It has increased from 41.03 (Mar 24) to 43.74, marking an increase of 2.71.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 43.74. It has increased from 41.03 (Mar 24) to 43.74, marking an increase of 2.71.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 44.06. It has increased from 41.48 (Mar 24) to 44.06, marking an increase of 2.58.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 5.84. This value is within the healthy range. It has decreased from 6.11 (Mar 24) to 5.84, marking a decrease of 0.27.
- For PBIT / Share (Rs.), as of Mar 25, the value is 4.76. This value is within the healthy range. It has decreased from 4.78 (Mar 24) to 4.76, marking a decrease of 0.02.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.67. This value is within the healthy range. It has decreased from 3.76 (Mar 24) to 3.67, marking a decrease of 0.09.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.60. This value is within the healthy range. It has decreased from 2.69 (Mar 24) to 2.60, marking a decrease of 0.09.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 3.24. This value is within the healthy range. It has decreased from 4.73 (Mar 24) to 3.24, marking a decrease of 1.49.
- For PBDIT Margin (%), as of Mar 25, the value is 13.24. This value is within the healthy range. It has decreased from 14.73 (Mar 24) to 13.24, marking a decrease of 1.49.
- For PBIT Margin (%), as of Mar 25, the value is 10.79. This value is within the healthy range. It has decreased from 11.52 (Mar 24) to 10.79, marking a decrease of 0.73.
- For PBT Margin (%), as of Mar 25, the value is 8.32. This value is below the healthy minimum of 10. It has decreased from 9.07 (Mar 24) to 8.32, marking a decrease of 0.75.
- For Net Profit Margin (%), as of Mar 25, the value is 5.89. This value is within the healthy range. It has decreased from 6.47 (Mar 24) to 5.89, marking a decrease of 0.58.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.35. This value is below the healthy minimum of 8. It has decreased from 11.40 (Mar 24) to 7.35, marking a decrease of 4.05.
- For Return on Networth / Equity (%), as of Mar 25, the value is 7.41. This value is below the healthy minimum of 15. It has decreased from 11.52 (Mar 24) to 7.41, marking a decrease of 4.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.13. This value is within the healthy range. It has decreased from 10.68 (Mar 24) to 10.13, marking a decrease of 0.55.
- For Return On Assets (%), as of Mar 25, the value is 5.07. This value is within the healthy range. It has decreased from 7.68 (Mar 24) to 5.07, marking a decrease of 2.61.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 0.2. It has decreased from 0.07 (Mar 24) to 0.04, marking a decrease of 0.03.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.20. This value is within the healthy range. It has decreased from 0.25 (Mar 24) to 0.20, marking a decrease of 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.70. There is no change compared to the previous period (Mar 24) which recorded 0.70.
- For Current Ratio (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.90 (Mar 24) to 1.95, marking an increase of 0.05.
- For Quick Ratio (X), as of Mar 25, the value is 1.41. This value is within the healthy range. It has decreased from 1.44 (Mar 24) to 1.41, marking a decrease of 0.03.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.24. This value is within the healthy range. It has increased from 1.21 (Mar 24) to 5.24, marking an increase of 4.03.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 15.42. This value is below the healthy minimum of 20. It has increased from 10.57 (Mar 24) to 15.42, marking an increase of 4.85.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 11.57. This value is below the healthy minimum of 20. It has increased from 8.25 (Mar 24) to 11.57, marking an increase of 3.32.
- For Earning Retention Ratio (%), as of Mar 25, the value is 84.58. This value exceeds the healthy maximum of 70. It has decreased from 89.43 (Mar 24) to 84.58, marking a decrease of 4.85.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 88.43. This value exceeds the healthy maximum of 70. It has decreased from 91.75 (Mar 24) to 88.43, marking a decrease of 3.32.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.35. This value is within the healthy range. It has decreased from 6.00 (Mar 24) to 5.35, marking a decrease of 0.65.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.38. This value is within the healthy range. It has decreased from 3.64 (Mar 24) to 3.38, marking a decrease of 0.26.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,419.92. It has decreased from 2,092.17 (Mar 24) to 1,419.92, marking a decrease of 672.25.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.50. This value exceeds the healthy maximum of 3. It has decreased from 5.48 (Mar 24) to 3.50, marking a decrease of 1.98.
- For EV / EBITDA (X), as of Mar 25, the value is 26.43. This value exceeds the healthy maximum of 15. It has decreased from 37.19 (Mar 24) to 26.43, marking a decrease of 10.76.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.33. This value exceeds the healthy maximum of 3. It has decreased from 5.28 (Mar 24) to 3.33, marking a decrease of 1.95.
- For Retention Ratios (%), as of Mar 25, the value is 84.57. This value exceeds the healthy maximum of 70. It has decreased from 89.42 (Mar 24) to 84.57, marking a decrease of 4.85.
- For Price / BV (X), as of Mar 25, the value is 3.35. This value exceeds the healthy maximum of 3. It has decreased from 5.34 (Mar 24) to 3.35, marking a decrease of 1.99.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.33. This value exceeds the healthy maximum of 3. It has decreased from 5.28 (Mar 24) to 3.33, marking a decrease of 1.95.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Themis Medicare Ltd:
- Net Profit Margin: 5.89%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.13% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 7.41% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.38
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.41
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 50.4)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.2
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 5.89%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot No.69-A, GIDC Industrial Estate, Valsad District Gujarat 396195 | cfoassist@themismedicare.com http://www.themismedicare.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Dinesh S Patel | Chairman & Executive Director |
| Dr. Sachin D Patel | Managing Director & CEO |
| Mr. Rajneesh K Anand | Non Executive Director |
| Dr. Adam Demeter | Non Executive Director |
| Ms. Manjul Sandhu | Independent Director |
| Mr. Bhaskar V Iyer | Independent Director |
| Mr. Nikunt K Raval | Independent Director |
| Ms. Neha Thakore | Independent Director |
| Mr. Shishir V Dalal | Independent Director |
| Mrs. Reena S Patel | Alternate Director |
FAQ
What is the intrinsic value of Themis Medicare Ltd?
Themis Medicare Ltd's intrinsic value (as of 28 October 2025) is 40.27 which is 68.54% lower the current market price of 128.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,179 Cr. market cap, FY2025-2026 high/low of 317/98.0, reserves of ₹393 Cr, and liabilities of 588 Cr.
What is the Market Cap of Themis Medicare Ltd?
The Market Cap of Themis Medicare Ltd is 1,179 Cr..
What is the current Stock Price of Themis Medicare Ltd as on 28 October 2025?
The current stock price of Themis Medicare Ltd as on 28 October 2025 is 128.
What is the High / Low of Themis Medicare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Themis Medicare Ltd stocks is 317/98.0.
What is the Stock P/E of Themis Medicare Ltd?
The Stock P/E of Themis Medicare Ltd is .
What is the Book Value of Themis Medicare Ltd?
The Book Value of Themis Medicare Ltd is 43.7.
What is the Dividend Yield of Themis Medicare Ltd?
The Dividend Yield of Themis Medicare Ltd is 0.39 %.
What is the ROCE of Themis Medicare Ltd?
The ROCE of Themis Medicare Ltd is 10.4 %.
What is the ROE of Themis Medicare Ltd?
The ROE of Themis Medicare Ltd is 7.65 %.
What is the Face Value of Themis Medicare Ltd?
The Face Value of Themis Medicare Ltd is 1.00.